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Abstract
Background: Elderly patients are at high risk of complications after stroke, such as infections and fever. The occurrence
of these complications has been associated with an increased risk of death or dependency.
Hypothesis: Prevention of aspiration, infections, or fever with metoclopramide, ceftriaxone, paracetamol, or any
combination of these in the first four days after stroke onset will improve functional outcome at 90 days in elderly
patients with acute stroke.
Design: International, 3 2-factorial, randomised-controlled, open-label clinical trial with blinded outcome assessment
(PROBE) in 3800 patients aged 66 years or older with acute ischaemic stroke or intracerebral haemorrhage and an
NIHSS score  6. Patients will be randomly allocated to any combination of oral, rectal, or intravenous metoclopramide
(10 mg thrice daily); intravenous ceftriaxone (2000 mg once daily); oral, rectal, or intravenous paracetamol (1000 mg
four times daily); or usual care, started within 24 h after symptom onset and continued for four days or until complete
recovery or discharge from hospital, if earlier.
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Outcome: The primary outcome measure is the score on the modified Rankin Scale at 90 days ( 14 days), as analysed
with multiple regression.
Summary: This trial will provide evidence for a simple, safe and generally available treatment strategy that may reduce
the burden of death or disability in patients with stroke at very low costs.
Planning: First patient included in May 2016; final follow-up of the last patient by April 2020.
Registration: ISRCTN, ISRCTN82217627, https://doi.org/10.1186/ISRCTN82217627
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Introduction
In the first days after stroke, about half of all patients
develop complications, including infections and fever.
The risk of developing these events is greater in patients
of higher age or with more severe stroke.1–3 Aspiration,
infections and fever can impede functional recovery,
prolong hospital admissions, and are independently
associated with an increased risk of death or long-
term dependency.1,2,4–9 In addition, systematic review
of animal studies modelling ischaemic stroke has
shown that hyperthermia during or shortly after the
onset of ischaemia substantially increases infarct size,
suggesting that the relation between fever and poor
outcome observed in patients is at least in part causal.10
The risk of developing these complications can be
reduced by very simple, safe and inexpensive measures,
such as metoclopramide for the management of dyspha-
gia, antibiotics for the prevention of infections and para-
cetamol for the prevention of fever, but it is uncertain
whether these measures also improve functional out-
come.11–14 In some, generally small, randomised trials,
preventive treatment with these drugs not only convinc-
ingly reduced the risks of aspiration, infections, or fever
by one third to one half, but was also associated with
clear trends towards a lower risk of death or poor out-
come.11–14 The cluster-randomised Quality in Acute
Stroke Care (QASC) study demonstrated that imple-
mentation of nursing protocols for the management of
fever, hyperglycaemia and swallowing dysfunction on a
stroke unit resulted in better outcomes.15 However, in
two recent large trials, preventive treatment with anti-
biotics did not improve functional outcomes.16,17
American guidelines for the treatment of patients
with acute ischaemic stroke advocate screening for
dysphagia; the use of antibiotics in patients with infec-
tions; and antipyretic drugs such as paracetamol in
patients with subfebrile temperatures or fever.18
Guidelines of the European Stroke Organisation
concluded that there is insufficient evidence from rand-
omised trials to make strong recommendations on
whether, when and to whom preventive antibiotic or
antipyretic treatment should be given after ischaemic
stroke or intracerebral haemorrhage.19,20 The authors
called for randomised trials to allow for better-
informed recommendations in the future.20
The PREvention of Complications to Improve
OUtcome in elderly patients with acute Stroke
(PRECIOUS) trial will assess whether a pharmacologi-
cal strategy to prevent aspiration, infections, or fever
with metoclopramide, ceftriaxone, paracetamol, or any
combination of these in elderly patients with a moder-
ately severe to severe acute stroke is more effective at
reducing the risk of death and improving functional out-
come than current clinical practice of waiting until these
complications are manifest before initiating treatment.
Design
Overview and timelines
PRECIOUS is an international, multi-centre, 3 2-
factorial, randomised, controlled, open-label clinical
trial with blinded outcome assessment (PROBE) of
the preventive use of metoclopramide, ceftriaxone,
paracetamol, or any combination of these, for four
days in elderly patients with acute ischaemic stroke or
intracerebral haemorrhage. The primary outcome mea-
sure is the score on the modified Rankin Scale (mRS) at
90 days (14 days).21 3800 patients will be recruited
over a period of about four years in about 80 hospitals
(both academic and regional) in 9 European countries
(Figure 1). The first patient was included in May 2016
and the main results are anticipated to be available in
2020. The complete and most recent version of the
study protocol is available at www.precious-trial.eu.
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Study population
The study population consists of patients aged 66 years
or older who are hospitalised with moderately severe to
severe acute ischaemic stroke or intracerebral haemor-
rhage and can be treated within 24 h of stroke onset.
In order to be eligible to participate, a patient must
meet all inclusion criteria listed in Table 1 and none
of the exclusion criteria listed in Table 2. Patients with
an active infection are excluded.
Patient enrolment
After written informed consent, patients are randomly
allocated in a 3 2 factorial design to any combination
of open-label oral, rectal, or intravenous metoclopra-
mide (10 mg thrice daily); intravenous ceftriaxone
(2000 mg once daily); oral, rectal, or intravenous
paracetamol (1000 mg four times daily); or usual
care, started within 24 h after symptom onset and con-
tinued for four days or until complete recovery or dis-
charge from hospital, if earlier (Figure 2). The daily
dose of metoclopramide is reduced to 3 times 5 mg in
patients with moderate to severe renal impairment or
with severe hepatic impairment, and to 3 times 2.5 mg
in patients with end-stage renal disease.
Allocation is based on proportional minimisation
through a web-based allocation service. Treatment
allocation is stratified by country and includes the
following minimisation factors for balance in baseline
characteristics: age (66–75 years vs.> 75 years); sex
(male vs. female); stroke type (ischaemic stroke vs.
intracerebral haemorrhage); stroke severity (NIHSS
6–12 vs.> 12); and diabetes mellitus (yes vs. no).
Investigators have the opportunity to censor a single
randomisation stratum in a specific patient before ran-
domisation, for example in case of an allergy to one of
the study medications (Table 2). Alongside the study
treatment, all patients receive standard care as recom-
mended by national or international guidelines or local
protocols. This may include thrombolysis and endovas-
cular treatment for acute ischaemic stroke, and treat-
ment of hypertension for intracerebral haemorrhage.
Data collection and follow-up
Baseline characteristics assessed are listed in
Table 3. The presence of any treatment restriction,
the method of food intake and the vital signs
(including body temperature) are recorded at baseline
and during the first seven days of hospitalisation.
The recording and reporting period for all severe or
serious adverse events begins after randomisation
and ends on day 7, except for serious adverse reactions
and suspected unexpected serious adverse reactions
(SUSARs), which are recorded and reported up to 90
days. Death occurring before day 90 ( 14) is a study
secondary outcome and is always documented
and recorded.
At day 7 after admission to the hospital, or at dis-
charge if earlier, the score on the mRS is assessed.
During a follow-up visit at day 90 ( 14), the mRS
is assessed by a trained, certified investigator in a stan-
dard fashion according to each centre’s normal prac-
tice, and the interview is recorded with a digital video
camera. During this recording, no reference to the
treatment allocation is made. The videos are uploaded
and distributed for independent and blinded scoring
by three certified expert raters from the same country
as the patient. Additionally, the Barthel index (BI),22
Montreal Cognitive Assessment (MoCA)23 and
EuroQol 5D-5L (EQ-5D-5L) are assessed at 90 days,
Table 1. Inclusion criteria.
1. A clinical diagnosis of acute ischaemic stroke or intracerebral
haemorrhage, confirmed with CT or MRI scana
2. A score on the NIHSS  6, indicating moderately severe to
severe strokeb
3. Age 66 years or older
4. The possibility to start treatment within 24 h of symp-
tom onsetc
5. Written informed consentd
CT: computed tomography; MRI: magnetic resonance imaging; NIHSS:
National Institutes of Health Stroke Scale.
aA normal CT scan is considered compatible with ischaemic stroke.
bNIHSS is assessed at the time of inclusion.
cIn case of a stuttering stroke, treatment should start within 24 h of the
moment the first symptoms occurred.
dInformed consent is given by the patient, legal representative or inde-
pendent physician (depending on local and national regulations).
Figure 1. Participating countries in PRECIOUS.
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Table 2. Exclusion criteria.
1. Active infection requiring antibiotic treatmenta
2. Pre-stroke score on the mRS 4b
3. Death appearing imminent at the time of assessment
Criteria for censoring a treatment stratum:
For the metoclopramide stratum:
1. Hypersensitivity to metoclopramide or to any of the excipients;
2. Gastrointestinal haemorrhage, mechanical obstruction or gastro-intestinal perforation for which the stimulation
of gastrointestinal motility constitutes a risk;
3. Confirmed or suspected pheochromocytoma;
4. History of neuroleptic or metoclopramide-induced tardive dyskinesia;
5. Epilepsy;
6. Parkinson’s disease;
7. Use of levodopa or dopaminergic agonists;
8. Known history of methaemoglobinaemia with metoclopramide or of NADH cytochrome-b5 deficiency.
9. Clinical indication for the use of metoclopramide. Incidental use of metoclopramide before screening is not an exclusion criterion.
For the ceftriaxone stratum:
1. Known hypersensitivity to beta-lactam antibiotics;
2. Clinical indication for antibiotic treatment. The use of an antibiotic before screening is not an exclusion criterion.
For the paracetamol stratum:
1. Known hypersensitivity to paracetamol or any of the excipients;
2. Known severe hepatic insufficiency;
3. Chronic alcoholism;
4. Clinical indication for the use of paracetamol. Incidental use of paracetamol before screening is not an exclusion criterion.
mRS: modified Rankin Scale.
aAs judged by the treating clinical physician.
bScore 4 mRS: Moderately severe disability. Unable to attend to own body needs without assistance and unable to walk unassisted.
Figure 2. Treatment allocation will be based on proportional minimisation. Investigators will have the opportunity to censor a single
randomisation stratum in a specific patient before randomisation. Each of the 8 subgroups is expected to consist of approximately
475 patients.
294 European Stroke Journal 3(3)
as well as the patient’s location and number of nights
spent at home over the first 90 days after stroke.
Outcome events
The primary outcome measure is the score on the mRS
at 90 days (14).24 The mRS is an ordinal hierarchical
scale incorporating seven categories from 0 up to and
including 6 and describes the range of disability
encountered post stroke. ‘Death’ is assigned a score
of 6. Secondary outcomes are outlined in Table 4.
Infections will be categorised as diagnosed by the
clinician, and as judged by an independent adjudication
committee (masked to treatment allocation) according
to modified Centres for Disease Control and
Prevention criteria.25 The scoring algorithms for infec-
tions that will be used by this committee have been
described previously and are in line with recommenda-
tions of the Pneumonia in Stroke Consensus Group.26
Clostridium difficile infection will be defined as diar-
rhoea in combination with a positive Clostridium diffi-
cile toxin test.
Substudy
To detect selection of bacteria with third generation
cephalosporin resistance caused by increased antibiotic
pressure, a nested case-control substudy will be
Table 3. Baseline characteristics.
• Demographics: age; sex; ethnicity
• Comorbidities/medical history: atrial fibrillation; diabetes
mellitus; hypertension; pre-stroke mRS
• Concurrent drugs: use of any antipyretic, antibiotic, or
antiemetic drug in the three days before randomisation.
a
• Way of food intake on the day before the strokeb
• Treatment restrictionsc
• Dates and times: stroke onset, hospital admission
• Vital signs: blood pressure; pulse; body temperatured
• Neurological examination: NIHSS; location of the lesion
• Laboratory examinationse
• Results of chest X-ray and urine analysis if performed as part
of routine clinical practice
• Imaging results: stroke type: ischaemic stroke or intracerebral
haemorrhage
• Previous treatment: intravenous thrombolysis with alteplase;
intra-arterial treatment.
mRS: modified Rankin Scale; NIHSS: National Institutes of Health
Stroke Scale.
aAspirin in any formulation and in a daily dose of up to 300 mg is not
considered an antipyretic drug.
bThe method of feeding on the day before the stroke and at noon of the
relevant day will be recorded and classified as 1. normal food; 2. oral, soft
or fluids only; 3. nasogastric tube; 4. percutaneous endoscopic gastro-
stomy (PEG); 5. intravenous only; 6. none.
cThe presence of any treatment restriction will be recorded at baseline
and during the patients stay in the hospital, and will be classified as 1. Do
not resuscitate; 2. Do not intubate and ventilate; 3. Withholding other
treatments that may prolong life; 4. Withholding food; 5. Withholding
fluids; and 6. Palliation with morphine or a benzodiazepine. Any combi-
nation of these strategies is possible.
dBlood pressure, pulse and body temperature will be assessed at baseline
and at 12-h ( 3 h) intervals (where assessed as part of routine clinical
practice). Both rectal and tympanic thermometry are allowed.
eIf assessed at baseline as part of routine clinical practice, the following
laboratory tests will be collected: serum glucose; glomerular filtration
rate; C-reactive protein (CRP); alkaline phosphatase (ALP); gamma-glu-
tamyl transferase (GGT); alanine aminotransferase (ALT); and aspartate
aminotransferase (AST); leucocyte count and differential.
Table 4. Study outcomes.
Primary outcome
• Score on the mRSa
Secondary outcomes
At 7 days ( 1 day) or at discharge, if earlier:
• Infections in the first seven days ( 1 day; frequency, type and
C. difficile infections)b
• 3rd generation cephalosporin resistance in the first seven days
( 1 day)c
• Antimicrobial use during the complete hospital admission
for stroked
• SAEs in the first seven days
• In a subgroup of patients: presence of ESBL-produc-
ing bacteria.e
At 90 days ( 14 days):
• Death
• Unfavourable functional outcomef
• Disabilityg
• Cognitionh
• Quality of lifei
• Home timej
• Patient locationk
mRS: modified Rankin Scale; SAE: serious adverse event; ESBL: extend-
ed-spectrum beta-lactamase.
aAs assessed by three independent and blinded adjudicators based on a
video recording of an mRS interview at the follow-up visit after 90 days.
bInfections will be categorised as diagnosed by the clinician, and as judged
by an independent adjudication committee (masked to treat-
ment allocation).
cDetected as part of routine clinical practice.
dConverted to units of defined daily doses according to the classification
of the WHO Anatomical Therapeutic Chemical Classification System
with Defined Daily Doses Index.
eAs detected by PCR in a rectal swab.
fDefined as mRS 3 to 6.
gAssessed with the Barthel index (BI).28
hAssessed with the Montreal Cognitive Assessment (MoCA).29
iAssessed with the EuroQol 5D-5L (EQ-5D-5L).
jThe number of nights among the first 90 since stroke onset that are
spent in the patient’s own home or a relative’s home. Where final follow-
up occurs earlier, the last known placement will be extrapolated to
90 days.
kHospital; rehabilitation service; chronic nursing facility; home.
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performed in 1000 patients in 30 centres in different
participating countries. The presence of extended spec-
trum beta-lactamase (ESBL) producing bacteria will be
assessed with polymerase chain reaction (PCR). For
this purpose, two rectal swabs will be collected in
each patient, after specific informed consent, on admis-
sion and at day 7 ( 1 day, or at discharge, if earlier).
Sample size calculation and statistical analysis plan
The primary effect estimate will be the difference
between groups in the mRS scores obtained through
centralised adjudications and assessed using multiple
regression, and will be expressed as a mean difference
with 95% confidence interval. PRECIOUS is powered
to detect a statistically significant shift in the difference
in the proportion of patients with mRS 0 to 2 at
90 days, assuming an effect that leads to a 5% absolute
increase (from 36 to 41%)26 in the cumulative propor-
tion of patients with mRS 0 to 2 in any intervention
group, compared with controls. The effect size of 5% is
based on previous smaller studies and/or meta-analyses
thereof, performed in more general stroke popula-
tions.12–14,16 The statistical analyses will be performed
according to the intention-to-treat principle and adjust-
ed for the minimisation factors mentioned, other
relevant baseline characteristics, and treatment alloca-
tion for the other two strata of the trial. Three
separate primary analyses will be performed, looking
at the main effects of each of the three interventions
compared with their respective controls. Although the
study is not powered to detect interactions between
the three interventions, such interactions will be inves-
tigated in secondary analyses. Two sensitivity analyses
will be performed in which all patients who are lost
to follow-up will be classified as having the worst pos-
sible outcome (death) or the best possible outcome
(mRS¼ 0), respectively.
Secondary efficacy outcomes will be analysed using
similar methods as for the primary efficacy analysis,
with binary logistic regression used for binary out-
comes, including death, unfavourable outcome and
SAEs. Ordinal logistic regression will be used for
ordered categorical data and multiple regression
for continuous outcomes. Wilcoxon rank sum test
will be used for continuous outcome measures which
are not normally distributed. Several subgroup analy-
ses will be performed based on age, sex, stroke type and
severity, diabetes mellitus, presence of atrial fibrilla-
tion, pre-stroke mRS score, treatment with alteplase
or other recanalisation method, treatment allocation
for the other two trial strata and time to treatment.
A full statistical analysis plan will be completed
before the final follow-up of the last patient.
Discussion
Because several complications in the first days after
stroke have consistently been associated with a higher
risk of death or poor functional outcome, prevention of
these complications appears a logical, simple and safe
approach to improve outcome after stroke. In the past
two decades, several trials aimed at prevention of
complications have been performed, but – besides
organised care in a designated stroke unit – no treat-
ment to prevent complications has convincingly shown
to improve the functional outcome in patient with
stroke.13,14,16 However, most of these trials were under-
powered, started treatment too late after stroke onset,
or aimed at only one specific complication after stroke.
Strengths of PRECIOUS are the assessment in an
elderly population with moderately severe to severe
stroke (with an increased risk of complications and
poor outcome), the start of treatment within 24 h
after stroke onset, and its multifactorial design. The
trial will provide high-quality evidence that could be
broadly generalisable. Because of its pragmatic design
and the use of safe, inexpensive, and generally available
drugs, the results of PRECIOUS could be implemented
rapidly throughout Europe and the rest of the world.
It may be questioned whether the effects of prophy-
lactic antibiotics in patients with stroke should still be
assessed after the neutral results in two recent phase III
clinical trials. Ceftriaxone is an off-patent, broad-
spectrum antibiotic with proven efficacy against bacte-
ria most frequently causing infection in patients with
acute stroke.12,27 In the PASS trial, 2550 patients with
stroke were randomly assigned to standard care or
intravenous ceftriaxone, started within 24 h of stroke
onset, continued for four days. Preventive ceftriaxone
reduced the incidence of infections in general (from 7%
to 3%; p< 0.0001), but did not have an effect on the
occurrence of pneumonia or the risk of a poor outcome
at 90 days.16 However, the median score on the NIHSS
of patients in PASS-was 5, which could explain the
relatively low incidence of infections. In the cluster-
randomised STROKE-INF trial, which included 1217
stroke patients with dysphagia, prophylactic antibiotics
did not change the incidence of post-stroke pneumonia
or poor functional outcome.17 However, antibiotic
treatment may have started too late (up to 48 h after
stroke onset) to prevent early infections. In addition, a
considerable proportion of patients in the treatment
group received only a limited number of antibiotic
doses, while 34% of the patients in the control group
received an antibiotic at least once during the first
seven days. Finally, individual centres included only a
small number of patients over an extended period of
time; in a cluster-randomised study, this may induce
selection bias decreasing the discriminative power.
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Because of the limitations of these two trials, and the
strong association between infections and a poor func-
tional outcome,4,28 additional evidence on the effect of
preventive antibiotics is still strongly needed.
The PRECIOUS trial will also be able to assess
whether antibiotics work in isolation, or whether the
effect is dependent on the combination of drugs that
are used in the trial. The results of PASS and
STROKE-INF support the concept that post-stroke
pneumonia might be a respiratory syndrome resulting
from complex bacterial, chemical and immunological
causes that might not be prevented by antibiotics
alone. The combination of treatments in PRECIOUS,
especially the combination of metoclopramide and cef-
triaxone, targets different pathways in the development
of post-stroke pneumonia, potentially resulting in a
larger reduction in the risk of complications than
with the individual treatments alone.
The prevention of complications with the treatments
proposed in PRECIOUS was safe in previous trials and
not associated with an increased risk of SAEs.13,14,16
In addition, the risk of developing Clostridium difficile
overgrowth was smaller than 1% in previous studies
with ceftriaxone, and there was no association with
an increase in antimicrobial resistance.16,17
PRECIOUS uses paracetamol for the prevention of
increases in body temperature because this was safe in
doses up to 6 g per day in randomised clinical trials
in patients with acute stroke, reduced the risk of sub-
febrile temperatures or fever at 24 h by 50% and was
associated with a trend towards an improvement in
functional outcome in the PAIS trial. This trial was
underpowered to detect a benefit on functional out-
come because this was terminated prematurely due to
lack of funding after inclusion of 1400 patients, against
a target of 2500 patients.10 For PRECIOUS, we have
selected a maximum daily dose of 4 g to comply with
the drug’s summary of product characteristics.
Given the potential benefit of the prevention of com-
plications to the patients included in PRECIOUS,
future stroke patients, their caregivers, and society,
the risk-benefit balance is strongly in favour of con-
ducting this clinical trial.
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